PMV Pharmaceuticals (NASDAQ:PMVP) Downgraded by Zacks Investment Research to Sell

0
92

PMV Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  PMV Pharmaceuticals Downgraded by Zacks Investment Research on 10/19/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of PMV Pharmaceuticals traded up $0.03 on Monday, reaching $23.80. 95557 shares of the stock traded hands, compared to its average volume of 429515. Shares of PMV Pharmaceuticals were trading at $23.80 on Monday. The firm’s 50 day moving average is $29.18 and its 200 day moving average is $34.22.PMV Pharmaceuticals has a 12 month low of $23.36 and a 12 month high of $63.22. While on yearly highs and lows, PMV Pharmaceuticals’s today has traded high as $24.45 and has touched $23.36 on the downward trend. See More Analyst Rating at: RATING

PMV Pharmaceuticals Earnings and What to expect: 

PMV Pharmaceuticals last released its quarterly earnings data on August 12th, 2021. The reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. PMV Pharmaceuticals has generated ($2.40) earnings per share over the last year ($1.52 diluted earnings per share) and currently has a price-to-earnings ratio of 15.7. Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.18) to ($1.51) per share. PMV Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, November 12th, 2021 based off prior year’s report dates.

Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.18) to ($1.51) per share. The P/E ratio of PMV Pharmaceuticals is 15.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.15. The P/E ratio of PMV Pharmaceuticals is 15.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 32.46. PMV Pharmaceuticals has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

PMV Pharmaceuticals (NASDAQ:PMVP) Moving Average Technical Analysis

5 day Moving Average is $23.86 And 5 day price change is -$0.01 (-0.02%)  with average volume for 5 day average is 343,441. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $27.39 and 20 day price change is -$3.50 (-12.74%) and average 20 day moving volume is 335,060. 50 day moving average is $29.18  and 50 day price change is -$11.48 ( -32.40%)  and with average volume for 50 days is : 396,632. 200 day moving average is $34.22  and 200 day price change is -$25.31 (-51.38%)  and with average volume for 200 days is : 278,473.

Other owners latest trading in PMV Pharmaceuticals :

  • On 10/19/2021 shares held by Interwest Venture Management Co. were 3,869,911 which equates to market value of $115.32M and appx 47.80% owners of PMV Pharmaceuticals
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 22,663 which equates to market value of $0.77M and appx 0.00% owners of PMV Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 68,328 which equates to market value of $2.34M and appx 0.00% owners of PMV Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 93.30% for PMV Pharmaceuticals

See More Analyst Rating at: RATING